H. Lundbeck A/S - Product Pipeline Review - 2015

Published: Apr, 2015 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's, 'H. Lundbeck A/S - Product Pipeline Review - 2015', provides an overview of the H. Lundbeck A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of H. Lundbeck A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of H. Lundbeck A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of H. Lundbeck A/S's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the H. Lundbeck A/S's pipeline products

Reason To Buy

- Evaluate H. Lundbeck A/S's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of H. Lundbeck A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the H. Lundbeck A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of H. Lundbeck A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of H. Lundbeck A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of H. Lundbeck A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
H. Lundbeck A/S Snapshot 6
H. Lundbeck A/S Overview 6
Key Information 6
Key Facts 6
H. Lundbeck A/S - Research and Development Overview 7
Key Therapeutic Areas 7
H. Lundbeck A/S - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
H. Lundbeck A/S - Pipeline Products Glance 16
H. Lundbeck A/S - Late Stage Pipeline Products 16
Filing rejected/Withdrawn Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
H. Lundbeck A/S - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
H. Lundbeck A/S - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
H. Lundbeck A/S - Drug Profiles 22
carbamazepine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
clobazam 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
droxidopa 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
idalopirdine 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
vortioxetine hydrobromide 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
LuAF-11167 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
LUAF-20513 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LuAF-35700 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
tedatioxetine 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
KW-6356 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
LUAF-64280 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AF-40431 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Inhibit LRRK-2 for Parkinson's Disease 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
H. Lundbeck A/S - Pipeline Analysis 42
H. Lundbeck A/S - Pipeline Products by Target 42
H. Lundbeck A/S - Pipeline Products by Route of Administration 45
H. Lundbeck A/S - Pipeline Products by Molecule Type 46
H. Lundbeck A/S - Pipeline Products by Mechanism of Action 47
H. Lundbeck A/S - Recent Pipeline Updates 49
H. Lundbeck A/S - Dormant Projects 60
H. Lundbeck A/S - Discontinued Pipeline Products 61
Discontinued Pipeline Product Profiles 61
gaboxadol 61
LuAA-47070 61
desmoteplase 62
idalopirdine 62
Lu-02750 62
Lu-35138 62
Lu-AA24493 62
LuAA-37096 62
LuAA-38466 63
LuAA-39959 63
LuAA-44608 63
LuAE-04621 63
ORE-10002 63
siramesine 63
tedatioxetine 64
zicronapine 64
H. Lundbeck A/S - Company Statement 65
H. Lundbeck A/S - Locations And Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

H. Lundbeck A/S, Key Information 6
H. Lundbeck A/S, Key Facts 6
H. Lundbeck A/S - Pipeline by Indication, 2015 9
H. Lundbeck A/S - Pipeline by Stage of Development, 2015 10
H. Lundbeck A/S - Monotherapy Products in Pipeline, 2015 11
H. Lundbeck A/S - Partnered Products in Pipeline, 2015 12
H. Lundbeck A/S - Partnered Products/ Combination Treatment Modalities, 2015 13
H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2015 14
H. Lundbeck A/S - Out-Licensed Products/ Combination Treatment Modalities, 2015 15
H. Lundbeck A/S - Filing rejected/Withdrawn, 2015 16
H. Lundbeck A/S - Phase III, 2015 17
H. Lundbeck A/S - Phase II, 2015 18
H. Lundbeck A/S - Phase I, 2015 19
H. Lundbeck A/S - Preclinical, 2015 20
H. Lundbeck A/S - Discovery, 2015 21
H. Lundbeck A/S - Pipeline by Target, 2015 43
H. Lundbeck A/S - Pipeline by Route of Administration, 2015 45
H. Lundbeck A/S - Pipeline by Molecule Type, 2015 46
H. Lundbeck A/S - Pipeline Products by Mechanism of Action, 2015 48
H. Lundbeck A/S - Recent Pipeline Updates, 2015 49
H. Lundbeck A/S - Dormant Developmental Projects,2015 60
H. Lundbeck A/S - Discontinued Pipeline Products, 2015 61
H. Lundbeck A/S, Subsidiaries 66